Revised CAR-T therapy eliminates dangerous cytokine release syndrome in lymphoma trial

Autologous CAR-T treatments for leukemia and lymphoma have offered new hope for patients, but the cell therapies can cause a dangerous immune reaction called cytokine release syndrome (CRS). Researchers at the University of Southern California (USC) Norris Comprehensive Cancer Center have designed a new type of CAR-T therapy to eliminate that side effect. CRS is a systemic inflammatory response...

Inovio publishes early positive results for dBiTEs cancer/leukemia approach

BiTE ( bispecific T-cell engager ) therapy is a relatively new approach in immunotherapy for cancer. BiTEs are used to help direct tumor killing cells to cancerous tumors, and the effect ranges from slowing cancer tumor growth, to completely halting it. One problem with the current BiTE approach is the cost of generating the BiTE cells. Inovio thinks they...